Rheumatoid Arthritis
Conditions
Keywords
Arthritis, Rheumatoid
Brief summary
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA.
Detailed description
RA is characterized by persistent inflammation of peripheral joints, causing pain, stiffness, swelling, and warmth. The inflammation may cause progressive joint damage and destruction, resulting in deformity and loss of function. Both traditional and biologic disease-modifying antirheumatic drugs (DMARDs) have been prescribed for RA patients to control existing inflammatory symptoms and affect long-term prognosis. However, DMARD use is expensive, and the long-term safety of DMARDs is unknown. Lovastatin is an HMG-CoA reductase inhibitor (also known as a statin) used to lower levels of cholesterol and other fats in the blood. The purpose of this study is to examine the safety and efficacy of lovastatin in controlling inflammation in individuals with RA who have mildly active RA disease despite treatment. Participants will be randomly assigned to one of two study arms (Experimental or Placebo). There will be four study visits over 12 weeks. At each visit, a physical exam, vital signs measurement, medication history, a pregnancy test (if applicable), and blood collection will occur. Additional safety blood testing will occur at Week 2. Tender and swollen joint counts and a Physician Global Assessment will occur at study entry and Week 12. Participants will also be asked to complete self-assessments at study entry and Week 12.
Interventions
DRUGLovastatin
Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
DRUGPlacebo
Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Sponsors
Autoimmunity Centers of Excellence
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of RA as defined by 1987 American College of Rheumatology (ACR) criteria * Functional Class I, II, or III RA as defined by 1987 ACR criteria * Serum C-reactive protein (CRP) measurement of greater than 5 mg/L * Mildly active disease with at least one swollen and two tender joints, but no more than six swollen and eight tender joints * If on corticosteroids, dose must be stable and 10 mg/day prednisone (or equivalent) or less for at least 4 weeks prior to study entry * If on DMARD, dose must be stable for at least 4 weeks (methotrexate, leflunomide, azathioprine, etanercept, adalimumab, anakinra) or at least 3 months (hydroxychloroquine, gold, or abatacept) * Willing to use acceptable means of contraception
Exclusion criteria
* Serum creatinine level greater than 1.5 mg/dL * Currently taking a statin or have taken a statin within 12 weeks of study entry * History of an adverse reaction to a statin * Active or recent infection within 4 weeks of study entry * Myositis or an unexplained elevation in creatine phosphokinase (CPK) * Joint replacement surgery within 60 days of study entry or plan to undergo joint replacement surgery during the course of the study * Intra-articular cortisone injections within 4 weeks of study entry * Chronic disorders other than RA affecting the joints, including systemic lupus erythematosus (SLE), psoriatic arthritis, gout, scleroderma, or known reactive arthritis (Reiter's syndrome) * HIV infection * Hepatitis B surface antigen positive * Hepatitis C antibody positive * Treatment with infliximab within 12 weeks of study entry * Treatment with rituximab * Treatment with medications known to be metabolized by the cytochrome P3A4 pathway. More information about this criterion can be found in the protocol. * Require amiodarone or verapamil * Investigational drug or treatment during the 4 weeks or seven half-lives prior to study entry * History of alcohol abuse * History of liver disease, current liver disease (e.g., hepatitis, cirrhosis), or abnormal liver function (AST or ALT greater than 2 times the upper limit of normal \[ULN\]) * Any condition that, in the opinion of the investigator, may interfere with the study * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Hematocrit (Hct) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Red Cell Distribution Width (RDW) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation. |
| Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
| Change From Baseline in CPK at Day 84 | Baseline (Day 0), Day 84 (Wk 12) | Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology) | Day 84 (Wk 12) | Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis. |
| Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | Baseline (Day 0), Day 84 (Wk 12) | Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was \<0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis. |
| Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | Baseline ( Day 0), Day 84 (Wk 12) | Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was \<8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis. |
| Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84 | Baseline (Day 0) to Day 84 (Wk 12) | The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (\>5.1=high disease activity; 3.2-\<=5.1=moderate disease activity; \<=3.2=low disease activity; \<2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis. |
Countries
United States
Participant flow
Recruitment details
Fifteen sites in the United States participated. The first site was activated in August 2006. The first participant was randomized in November 2007 and the last participant was randomized in February 2012.
Participants by arm
| Arm | Count |
|---|---|
| Lovastatin 80 mg Participants were randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes. | 34 |
| Placebo Participants were randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188. | 29 |
| Total | 63 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Elevated SGOT (AST) lab value | 0 | 1 |
| Overall Study | Physician Decision | 1 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 3 |
Baseline characteristics
| Characteristic | Placebo | Total | Lovastatin 80 mg |
|---|---|---|---|
| Age, Continuous | 52.6 years STANDARD_DEVIATION 10.4 | 54.3 years STANDARD_DEVIATION 8.8 | 55.8 years STANDARD_DEVIATION 7.1 |
| C-reactive Protein (CRP) Level at Baseline | 12.6 mg/L STANDARD_DEVIATION 16.4 | 12.4 mg/L STANDARD_DEVIATION 13.8 | 12.2 mg/L STANDARD_DEVIATION 11.4 |
| Disease Activity Score Using C-reactive Protein (DAS28-CRP) | 4.2 scores on a scale STANDARD_DEVIATION 0.4 | 4.0 scores on a scale STANDARD_DEVIATION 0.6 | 3.9 scores on a scale STANDARD_DEVIATION 0.7 |
| Number of Participants at Baseline Who Were Taking a Biologic Drug | 11 Participants | 31 Participants | 20 Participants |
| Number of Participants at Baseline Who Were Taking an Anti-TNF Drug | 10 Participants | 26 Participants | 16 Participants |
| Number of Participants at Baseline Who Were Taking Methotrexate | 16 Participants | 36 Participants | 20 Participants |
| Patient Global Assessment of Disease Activity - Visual Analog Scale (VAS) | 4.5 cm STANDARD_DEVIATION 1.6 | 4.0 cm STANDARD_DEVIATION 2 | 3.5 cm STANDARD_DEVIATION 2.3 |
| Region of Enrollment United States | 29 participants | 63 participants | 34 participants |
| Sex: Female, Male Female | 28 Participants | 60 Participants | 32 Participants |
| Sex: Female, Male Male | 1 Participants | 3 Participants | 2 Participants |
| Swollen Joint Count at Baseline | 3.8 swollen joints STANDARD_DEVIATION 1.6 | 3.6 swollen joints STANDARD_DEVIATION 1.5 | 3.5 swollen joints STANDARD_DEVIATION 1.4 |
| Tender Joint Count at Baseline | 4.8 tender joints STANDARD_DEVIATION 2.2 | 4.6 tender joints STANDARD_DEVIATION 2.4 | 4.4 tender joints STANDARD_DEVIATION 2.5 |
| Years with Rheumatoid Arthritis at Baseline | 11.9 years STANDARD_DEVIATION 12.6 | 12.2 years STANDARD_DEVIATION 11 | 12.5 years STANDARD_DEVIATION 9.6 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 23 / 34 | 25 / 30 |
| serious Total, serious adverse events | 1 / 34 | 1 / 30 |
Outcome results
Primary
Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84
Blood draw for CRP, an acute phase reactant used to identify the presence of nonspecific inflammation. Change=Day 84 value minus Baseline value. Normal serum CRP reference range in this study is 0-4 mg/L (log transformed: -4.2 to 1.4). Participants with measurements for designated time points were included in analysis. An increased CRP level indicates the presence of inflammation. Reduced CRP levels could mean a decrease in inflammation.
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Intent-to-Treat with available data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84 | -0.4 mg/L | Standard Error 0.2 |
| Placebo | Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84 | -0.3 mg/L | Standard Error 0.1 |
Comparison: The p-value compares Lovastatin with the Placebo treatment group. Log transformed CRP was analyzed to meet the heterogeneity assumption for ANCOVA models.p-value: 0.79ANCOVA
Primary
Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Albumin | 0.0 g/dL | Standard Deviation 0.2 |
| Lovastatin 80 mg | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Total Protein | 0.0 g/dL | Standard Deviation 0.4 |
| Lovastatin 80 mg | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Hemoglobin | -0.3 g/dL | Standard Deviation 0.6 |
| Lovastatin 80 mg | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | MCHC | -0.3 g/dL | Standard Deviation 0.9 |
| Placebo | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | MCHC | -0.4 g/dL | Standard Deviation 1 |
| Placebo | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Albumin | 0.1 g/dL | Standard Deviation 0.3 |
| Placebo | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Hemoglobin | -0.3 g/dL | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Albumin, Total Protein, Hemoglobin, and Mean Corpuscular Hemoglobin Concentration (MCHC) at Day 84 | Total Protein | 0.1 g/dL | Standard Deviation 0.5 |
Primary
Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | Alkaline Phosphatase | -3.0 U/L | Standard Deviation 20.4 |
| Lovastatin 80 mg | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | ALT | -1.8 U/L | Standard Deviation 10.2 |
| Lovastatin 80 mg | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | AST | -1.2 U/L | Standard Deviation 19.7 |
| Placebo | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | Alkaline Phosphatase | 0.4 U/L | Standard Deviation 15.6 |
| Placebo | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | ALT | 0.7 U/L | Standard Deviation 10.2 |
| Placebo | Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84 | AST | 0.8 U/L | Standard Deviation 7.3 |
Primary
Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Monocytes | 0.1 10^3/uL | Standard Deviation 0.1 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Neutrophils | 0.2 10^3/uL | Standard Deviation 1 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Bands | 0.0 10^3/uL | Standard Deviation 0.1 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Lymphocytes | -0.1 10^3/uL | Standard Deviation 0.4 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Eosinophils | 0.0 10^3/uL | Standard Deviation 0.1 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Basophils | 0.0 10^3/uL | Standard Deviation 0 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Platelet Count | -8.2 10^3/uL | Standard Deviation 34.2 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Reticulocytes | -4.7 10^3/uL | Standard Deviation 15.6 |
| Lovastatin 80 mg | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | WBC | 0.1 10^3/uL | Standard Deviation 1 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Reticulocytes | 0.0 10^3/uL | Standard Deviation 0 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | WBC | -0.4 10^3/uL | Standard Deviation 1.3 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Eosinophils | 0.0 10^3/uL | Standard Deviation 0.2 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Neutrophils | -0.6 10^3/uL | Standard Deviation 1.3 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Platelet Count | -5.6 10^3/uL | Standard Deviation 56.8 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Bands | 0.0 10^3/uL | Standard Deviation 0.1 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Basophils | 0.0 10^3/uL | Standard Deviation 0 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Lymphocytes | 0.1 10^3/uL | Standard Deviation 0.8 |
| Placebo | Change From Baseline in Counts: White Blood Cells (WBC), Neutrophils, Bands, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets, and Reticulocytes at Day 84 | Monocytes | 0.0 10^3/uL | Standard Deviation 0.2 |
Primary
Change From Baseline in CPK at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in CPK at Day 84 | -2.4 U/L | Standard Deviation 51.2 |
| Placebo | Change From Baseline in CPK at Day 84 | 8.0 U/L | Standard Deviation 54 |
Primary
Change From Baseline in Hematocrit (Hct) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Hematocrit (Hct) at Day 84 | -0.5 % of packed red blood cells by volume | Standard Deviation 2.2 |
| Placebo | Change From Baseline in Hematocrit (Hct) at Day 84 | -0.5 % of packed red blood cells by volume | Standard Deviation 2.2 |
Primary
Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84 | -0.4 pg | Standard Deviation 0.7 |
| Placebo | Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Day 84 | 0.0 pg | Standard Deviation 1.3 |
Primary
Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84 | -0.4 fL | Standard Deviation 2.3 |
| Placebo | Change From Baseline in Mean Corpuscular Volume (MCV) at Day 84 | 0.7 fL | Standard Deviation 3.2 |
Primary
Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Potassium | 0.0 mmol/L | Standard Deviation 0.3 |
| Lovastatin 80 mg | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Sodium | -0.2 mmol/L | Standard Deviation 1.8 |
| Lovastatin 80 mg | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Chloride | -0.1 mmol/L | Standard Deviation 2.3 |
| Lovastatin 80 mg | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Total CO2 | 0.7 mmol/L | Standard Deviation 2.6 |
| Placebo | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Total CO2 | -0.5 mmol/L | Standard Deviation 2.3 |
| Placebo | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Potassium | 0.0 mmol/L | Standard Deviation 0.5 |
| Placebo | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Chloride | 0.5 mmol/L | Standard Deviation 3 |
| Placebo | Change From Baseline in Potassium, Sodium, Chloride, and Total CO2 at Day 84 | Sodium | -0.2 mmol/L | Standard Deviation 2.7 |
Primary
Change From Baseline in Red Cell Distribution Width (RDW) at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Red Cell Distribution Width (RDW) at Day 84 | -0.4 % of mean corpuscle volume | Standard Deviation 2 |
| Placebo | Change From Baseline in Red Cell Distribution Width (RDW) at Day 84 | 0.2 % of mean corpuscle volume | Standard Deviation 1.1 |
Primary
Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84
Blood samples were taken from participants at Baseline and Day 84. Participants with measurements for designated time points included in analysis. Change=Day 84 value minus Baseline value. A positive difference reflects an increased laboratory parameter value over time; a negative difference reflects a decreased laboratory parameter value over time. Normal laboratory values depend on a subject age, gender, and the specific laboratory methods that were used to determine the lab values. Reference: http://www.merckmanuals.com/professional/appendixes/normal\_laboratory\_values/blood\_tests\_normal\_values.html
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Safety
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Total Bilirubin | 0.0 mg/dL | Standard Deviation 0.2 |
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | BUN | -0.4 mg/dL | Standard Deviation 3.2 |
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Phosphorus | 0.0 mg/dL | Standard Deviation 0.5 |
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Creatinine | 0.0 mg/dL | Standard Deviation 0.1 |
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Calcium | 0.0 mg/dL | Standard Deviation 0.4 |
| Lovastatin 80 mg | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Glucose | -4.3 mg/dL | Standard Deviation 16.5 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Calcium | 0.0 mg/dL | Standard Deviation 0.3 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Glucose | -1.2 mg/dL | Standard Deviation 18.6 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Total Bilirubin | 0.1 mg/dL | Standard Deviation 0.2 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Creatinine | 0.0 mg/dL | Standard Deviation 0.1 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | BUN | -0.5 mg/dL | Standard Deviation 2.3 |
| Placebo | Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84 | Phosphorus | 0.0 mg/dL | Standard Deviation 0.5 |
Secondary
Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)
Anti-CCP antibodies are autoantibodies frequently detected in the serum of individuals with rheumatoid arthritis. In this study, a positive value for anti-CCP was 8 IU/mL or greater; a negative value for anti-CCP was \<8 IU/mL. Change= subtraction of Day 0 from Day 84 anti-CCP value. In general, high levels of the antibody indicate an aggressive rheumatoid arthritis and a higher risk of joint damage. Participants with measurements for designated time points included in analysis.
Time frame: Baseline ( Day 0), Day 84 (Wk 12)
Population: Intent-to-Treat with Available Data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | 16.3 IU/mL | Standard Error 12.1 |
| Placebo | Adjusted Mean Change From Baseline in Serum Anti-cyclic Citrullinated Peptide (Anti-CCP) by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | -1.0 IU/mL | Standard Error 13.5 |
Comparison: The p-value compares Lovastatin with the Placebo treatment group.p-value: 0.35ANCOVA
Secondary
Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay)
Rheumatoid factor (RF) is an antibody often present in the blood of a person with rheumatoid arthritis. In this study, a positive value for RF was 0.5 IU/mL or greater; a negative value for RF was \<0.5 IU/mL. Change= Day 84 value minus Baseline value. In general, presence of the antibody indicates aggressive rheumatoid arthritis and higher risk of joint damage. Participants with measurements for designated time points included in analysis.
Time frame: Baseline (Day 0), Day 84 (Wk 12)
Population: Intent-to-Treat with Available Data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | -5.4 IU/mL | Standard Error 4 |
| Placebo | Adjusted Mean Change From Baseline in Serum IgM Rheumatoid Factor by ELISA (ELISA: Enzyme-linked Immunosorbent Assay) | 2.8 IU/mL | Standard Error 4.5 |
Comparison: The p-value compares Lovastatin with the Placebo treatment group.p-value: 0.19ANCOVA
Secondary
Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84
The DAS28-CRP score is on a scale of 0 to 10 and indicates current activity of rheumatoid arthritis (\>5.1=high disease activity; 3.2-\<=5.1=moderate disease activity; \<=3.2=low disease activity; \<2.6=remission). The score uses a combination of four variables: 1) the number of tender joints (of the 28 that are measured); 2) the number of swollen joints (of the 28 that are measured); 3) serum C-reactive protein (CRP) lab value in mg/L , and 4) Patient Global Assessment of Disease Activity. Using a formula, the physician determines the score. Participants with measurements for designated time points included in analysis.
Time frame: Baseline (Day 0) to Day 84 (Wk 12)
Population: Intent-to-Treat with Available Data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lovastatin 80 mg | Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84 | -0.5 Scores on a scale | Standard Error 0.2 |
| Placebo | Adjusted Mean Change From Baseline in the Disease Activity Score Using C-reactive Protein (DAS28-CRP) on Day 84 | -0.5 Scores on a scale | Standard Error 0.2 |
Comparison: The p-value compares Lovastatin with the Placebo treatment group.p-value: 0.91ANCOVA
Secondary
Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology)
Patients were ACR20 Responders if they had: at least 20% improvement in both tender joint count (28 examined) and swollen joint count (28 examined), and 20% improvement in at least three of the following 5 remaining ACR core measures: • Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm) • Patient's global assessment of disease activity (VAS 100 mm) • Physician's global assessment of disease activity (VAS 100 mm) • Patient self-assessed disability (Health Assessment Questionnaire (HAQ)) score • Acute phase reactant C-reactive protein. Participants with measurements for designated time points were included in analysis.
Time frame: Day 84 (Wk 12)
Population: Intent-to-Treat with Available Data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lovastatin 80 mg | Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology) | 29.0 Percentage of participants |
| Placebo | Percentage of Participants Meeting ACR20 Response Criteria at Day 84 (ACR: American College of Rheumatology) | 40.0 Percentage of participants |
Comparison: The p-value compares Lovastatin with the Placebo treatment group.p-value: 0.3995% CI: [-35.9, 14]Chi-squared